Jia Fan-Jia
No. 180 Fenglin Road
Xuhui, 200032, China
Xuhui, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study.
Journal: The Lancet. Oncology
Published: May 08, 2026
Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: April 29, 2026
Correction: Multi-model analysis of gallbladder cancer reveals the role of OxLDL-absorbing neutrophils in promoting liver invasion.
Journal: Experimental hematology & oncology
Published: November 05, 2025
Neuroimmunometabolic co-evolution in the tumor micro- and macroenvironment.
Journal: Cell metabolism
Published: October 03, 2025
Activation of Nerve Growth Factor signaling limits the response to lenvatinib in hepatocellular carcinoma.
Journal: Signal transduction and targeted therapy
Published: September 16, 2025
Multi-omic profiling identifies TREM2+ lipid-laden macrophages as inflammatory drivers and therapeutic targets of colorectal cancer liver metastasis.
Journal: Cancer letters
Published: September 14, 2025
AdvanTIG-206: a phase II, randomized study of ociperlimab plus tislelizumab and BAT1706 (bevacizumab biosimilar) versus tislelizumab and BAT1706 in first-line hepatocellular carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: September 03, 2025
Autophagy-promoted immunogenic cell death elicited by tyrosine kinase inhibitor orchestrates a synergistic immunotherapeutic microenvironment in hepatocellular carcinoma.
Journal: Experimental hematology & oncology
Published: July 23, 2025
STAT3 induced BRD9 activation promotes intrahepatic cholangiocarcinoma progression by enhancing CD36 controlled fatty acid metabolism.
Journal: Cancer letters
Published: April 27, 2025
First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study.
Journal: Signal transduction and targeted therapy
Published: February 10, 2025
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: December 16, 2024
Last Updated: 09/26/2026